BofA analyst Alec Stranahan lowered Krystal Biotech’s price target to $182 from $192, maintaining a Buy rating. Q2 report had positives but concerns arise over near-term growth. Q3 revenue expected to be below Q2 due to patient pausing trends. Model updated to reflect decreased Vyjuvek revenues and delayed KB407 and KB408 launches.

Read more at Yahoo Finance: Krystal Biotech price target lowered to $182 from $192 at BofA